What is the difference between enclomiphene and testosterone injections?
Testosterone injections supply the hormone from outside the body. Enclomiphene is an oral SERM that reduces estrogen feedback at the hypothalamus and pituitary, increasing LH and FSH in men whose signalling axis and testes can respond.1 Exogenous testosterone generally suppresses LH, FSH, intratesticular testosterone and sperm production, but the degree and timing vary by person, dose and formulation.2
This page is for the man weighing injections specifically, the cheapest and most common way testosterone is prescribed. If you are still deciding at the category level, gels and pellets included, start with the full enclomiphene vs TRT picture. And one disclosure before the detail, because it shapes the cost and oversight questions below: enclomiphene is not an FDA-approved drug. Compounded enclomiphene products have not undergone FDA premarket review for safety, effectiveness or quality. FDA-approved injectable testosterone products have product-specific indications, dosing and monitoring instructions.
“The needle is not the decision. What happens to your own production is the decision.”
What do injections do to sperm and fertility?
The clearest injection data come from male-contraception research, not routine hypogonadism care. The World Health Organization gave 271 healthy fertile men 200 mg intramuscular testosterone enanthate weekly. In total, 157 men achieved confirmed azoospermia; the cumulative estimate by six months was 65%, and the mean time to azoospermia was 120 days. One pregnancy occurred during 1,486 person-months of the efficacy phase.3 That result shows substantial, incomplete sperm suppression. Testosterone should not be treated as dependable birth control.
Recovery of sperm after exogenous testosterone usually takes months, but the WHO study's endpoint was sperm concentration, not pregnancy, live birth, symptoms or testosterone recovery. Direct enclomiphene trials used testosterone gel, not injections, as the active comparator. In overweight men aged 18 to 60 with two early-morning testosterone results of 300 ng/dL or less and LH below 9.4 IU/L, 16 weeks of enclomiphene maintained sperm concentration while gel reduced it.4 That supports a biological difference, but it does not prove pregnancy or live-birth benefit.
Guidelines recommend against starting testosterone therapy in men planning fertility in the near term.5 For men already committed to injections, an adjunct exists: hCG injected alongside testosterone to keep the testes stimulated, which we cover in enclomiphene vs hCG. It is specialist territory, not an assurance of fertility. A retrospective series included only 26 men, 19 using injections and seven using gel; none became azoospermic and nine partner pregnancies were reported, but there was no untreated or testosterone-only control group.6
| Question | Direct evidence | What it cannot establish |
|---|---|---|
| Enclomiphene vs injections | No randomized head-to-head trial identified | Relative symptoms, pregnancy, live birth or long-term safety |
| Enclomiphene vs testosterone gel | Short trials measured hormones and sperm concentration4 | Results specific to injection dosing or peak-to-trough exposure |
| Weekly testosterone enanthate | WHO contraception trial: 157 men achieved confirmed azoospermia; cumulative estimate 65% by six months3 | Reliable contraception or outcomes in routine TRT dosing |
| Testosterone plus hCG | Uncontrolled n=26 series; no azoospermia, nine partner pregnancies6 | Comparative efficacy or guaranteed fertility preservation |
“If children are anywhere in your plans, say so before the first prescription, not after.”
How do the practical routines compare?
The routine depends on the product and prescription. Testosterone cypionate and enanthate can be given intramuscularly, while some products and clinician protocols use subcutaneous administration. Intervals differ, so once-weekly or split-dose schedules should not be presented as universal. Enclomiphene studies generally used daily oral dosing, but a compounded prescription may differ.
On the injection side, honesty cuts both ways. Many men self-inject comfortably from the first week and find a once-weekly rhythm easier to keep than a daily pill; some never get comfortable with needles at all, and knowing which man you are is legitimate input, not weakness. Missed doses show up in your levels on either schedule. What the routine cannot answer is which drug suits your biology; that question belongs to fertility, monitoring and eligibility, not to squeamishness in either direction.
Which is cheaper?
Generic injectable testosterone often has a lower cash price than a compounded enclomiphene program, but the amount a person pays depends on product, dose, pharmacy, insurance rules, memberships and required laboratory testing. Compounded drugs may be excluded by many plans, while coverage for FDA-approved testosterone still depends on the plan and prior-authorization criteria. Current price examples and their inclusions belong in our enclomiphene cost breakdown.
Compare the full first-year cost, not a vial or capsule price alone: visits, repeat labs, supplies, shipping and any membership can change the answer. No national list-price snapshot establishes what every patient or insurer pays.
What monitoring does each need?
Testosterone monitoring is individualized, but guidelines call for follow-up testosterone and hematocrit, with prostate assessment when age and risk make it appropriate. The Endocrine Society recommends stopping therapy when hematocrit exceeds 54%, evaluating for hypoxia and sleep apnea, then considering restart at a reduced dose.5 In 2025, FDA required class-wide blood-pressure warnings for testosterone products.7
On cardiovascular risk, the reference point is TRAVERSE, a 5,246-man randomized safety trial in men aged 45 to 80 with symptoms, two fasting testosterone results below 300 ng/dL, and existing or high cardiovascular risk. Major adverse cardiac events occurred in 7.0% on testosterone and 7.3% on placebo, meeting the trial's non-inferiority bar, but the testosterone group recorded more atrial fibrillation, more acute kidney injury and more pulmonary embolism. Mean treatment duration was 21.7 months and mean follow-up was 33.0 months.8 The trial tested a daily gel, so applying the result specifically to injections is an extrapolation.
There is no FDA-approved enclomiphene label that defines contraindications or a standard monitoring schedule. A 2025 meta-analysis pooled clomiphene and enclomiphene trials: estradiol was higher than placebo by 33.99 pg/mL (95% CI 19.19 to 48.79) and higher than testosterone gel by 18.35 pg/mL (95% CI 6.66 to 30.04).9 Those pooled SERM estimates are not a direct enclomiphene-versus-injection comparison. Advice to stop and seek care for visual symptoms comes from clomiphene labeling and class caution, not a US enclomiphene label.10
What happens when you stop each one?
After injections stop, drug levels fall. The suppressed hormone axis and sperm production may recover to a variable degree and on a variable timeline. Contraception studies show that sperm recovery generally takes months, but sperm is not the same endpoint as serum testosterone, symptoms or wellbeing. The extent and interval depend on the ester, exposure, baseline function and individual response, so neither complete recovery nor a universal date can be promised.11
Enclomiphene discontinuation is also sparsely studied. One trial observed hormonal effects for at least one week after the last dose.13 In another small study of 12 men, testosterone returned to pretreatment values one month after treatment ended.12 These small biochemical studies do not establish a symptom or fertility recovery timeline.
Who should choose which?
Testosterone replacement does not require the testes to increase their own output. Enclomiphene requires a responsive hypothalamic-pituitary-gonadal axis. In primary hypogonadism, where the testes themselves have failed, a signal-amplifying drug has nothing to work with. Injections instead supply exogenous testosterone without relying on endogenous testicular production; that mechanistic difference does not establish individual eligibility. If a clinician confirms an inadequate biochemical response, the diagnosis should be reassessed before another treatment is considered. Enclomiphene trials enrolled selected men with secondary hypogonadism, and their entry thresholds should not be mistaken for a universal prescribing rule.4 When fertility matters, semen analysis and reproductive goals deserve direct assessment rather than inference from testosterone alone.
Severe deficiency is a clinician's call either way, and severity can shift the answer toward replacement regardless of preference. The honest close: nobody should choose a hormone drug off a blog, including this one. A real workup measures LH and FSH so the diagnosis has a location, and a careful enclomiphene provider declines or investigates further when the evidence and mechanism make benefit unlikely. Who fits, and who should expect a no, is in who qualifies for enclomiphene.
Enclomiphene vs testosterone injections at a glance
A decision aid that separates direct findings from extrapolation.
| Decision point | Enclomiphene | Testosterone injections |
|---|---|---|
| Direct head-to-head injection trial | None identified | None identified |
| FDA status | Not FDA approved; compounded products lack FDA premarket review | FDA-approved products available; labeling varies by product |
| Your own production | LH and FSH increased in selected secondary-hypogonadism trials1 | LH, FSH and intratesticular testosterone are generally suppressed2 |
| Sperm | Concentration maintained versus gel over 16 weeks; no pregnancy or live-birth endpoint4 | 157 achieved confirmed azoospermia; cumulative estimate 65% by six months with 200 mg enanthate weekly; not reliable contraception3 |
| Monitoring | No authoritative US label schedule; pooled SERM data show estradiol rises9 | Testosterone, hematocrit and risk-based prostate monitoring; blood pressure warning57 |
| Cost and coverage | Often cash pay; include compounded drug, visits and labs | Generic cash prices may be lower; plan coverage and authorization vary |
| Recovery after stopping | Effects persisted at least one week in one trial; n=12 returned to pretreatment testosterone at one month in another1312 | May be incomplete and variable; contraception studies support months for sperm recovery, not a personal symptom timeline11 |
Common questions
Are testosterone injections stronger than enclomiphene?
There is no randomized direct trial showing that testosterone injections produce better symptom or health outcomes than enclomiphene. Enclomiphene has been compared mainly with testosterone gel.
Dose and timing can produce different blood levels, but a larger testosterone number is not proof of a better clinical outcome.
Can you stay fertile on testosterone injections?
Testosterone injections can markedly suppress sperm production but do not reliably prevent pregnancy. A small uncontrolled series of 26 men receiving testosterone plus low-dose hCG reported no azoospermia and nine partner pregnancies, but it cannot establish how well the combination preserves fertility.
Men planning fertility should discuss alternatives and semen testing with a fertility-literate clinician. See our enclomiphene vs hCG guide.
Do you have to inject testosterone forever?
No. After injections stop, drug levels fall. The suppressed hormone axis and sperm production may recover to a variable degree and on a variable timeline.
Male-contraception studies show sperm recovery generally takes months, but those sperm endpoints do not predict an individual's testosterone symptoms or recovery date. Stopping should be planned with the prescriber.
Can you switch from testosterone injections to enclomiphene?
Clinicians sometimes use a SERM after exogenous testosterone, but no controlled trial has established an enclomiphene switching protocol or a reliable recovery timeline.
A plan needs to account for the injectable ester, symptoms, LH and FSH, testosterone measurements and fertility goals.
References
- 1.Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and Sterility. 2014;102(3):720-727. doi:10.1016/j.fertnstert.2014.06.004.
- 2.Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. World Journal of Men's Health. 2019;37(1):45-54. doi:10.5534/wjmh.180036.
- 3.World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955-959. PMID: 1977002.
- 4.Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU International. 2016;117(4):677-685. doi:10.1111/bju.13337.
- 5.Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229.
- 6.Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology. 2013;189(2):647-650. doi:10.1016/j.juro.2012.09.043.
- 7.US Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug Safety Communication. February 28, 2025.
- 8.Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025.
- 9.Hohl A, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093.
- 10.US Food and Drug Administration. Clomid (clomiphene citrate) tablets prescribing information. Revised October 2012.
- 11.Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420. doi:10.1016/S0140-6736(06)68614-5.
- 12.Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone. Journal of Sexual Medicine. 2013;10(6):1628-1635. doi:10.1111/jsm.12116.
- 13.Wiehle R, et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU International. 2013;112(8):1188-1200. doi:10.1111/bju.12363.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. It does not create a clinician and patient relationship. Talk to a licensed clinician about your own situation, and call your doctor or 911 for anything urgent.